| The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. | |
| | |
MedLine Citation:
|
PMID: 18041998 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The 5-lipoxygenase pathway is responsible for the production of leukotrienes--inflammatory lipid mediators that have a role in innate immunity, but that can also have pathological effects in inflammatory diseases. Recently, a potential link between leukotriene production and atherosclerosis has been proposed. The expression of leukotriene biosynthetic enzymes and leukotriene receptors has been identified in coronary and carotid atherosclerotic plaques, and the levels of biosynthetic enzymes have been correlated with the clinical symptoms of unstable plaques. Genetic variants in 5-lipoxygenase pathway genes have also been associated with a relative risk of developing myocardial infarction and stroke. On the basis of these discoveries, antileukotriene compounds are now being evaluated for the treatment of cardiovascular disease. Several tool compounds have been shown to limit the progression of lesion development in preclinical models of atherosclerosis, and three compounds, including two drugs previously developed for asthma, are undergoing clinical trials in patients with acute coronary syndromes. |
| | |
Authors:
|
Carl Whatling; William McPheat; Margareta Herslöf |
Related Documents
:
|
12052268 - Early use of statins in acute coronary syndromes. 8656168 - Number-needed-to-treat analysis of the prevention of myocardial infarction and death by... 1263558 - Fatal cerebral atheromatous embolization after cardiopulmonary bypass. 9211018 - Retardation of coronary atherosclerosis: the bezafibrate coronary atherosclerosis inter... 8447498 - Chronic angiotensin-converting-enzyme inhibition improves cardiac output and fluid bala... 11389358 - Nonpharmacologic treatment of acute heart failure. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 16 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-11-28 Completed Date: 2008-02-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1879-93 Citation Subset: IM |
Affiliation:
|
AstraZeneca R&D Mölndal, Bioscience Department, Pepparedsleden 1, 431 83 Mölndal, Sweden. carl.whatling@astrazeneca.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Arachidonate 5-Lipoxygenase / antagonists & inhibitors, metabolism* Atherosclerosis / drug therapy, enzymology* Cardiovascular Diseases / drug therapy, enzymology Clinical Trials as Topic Drugs, Investigational / chemistry, pharmacology, therapeutic use* Humans Lipoxygenase Inhibitors / chemistry, pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Drugs, Investigational; 0/Lipoxygenase Inhibitors; EC 1.13.11.34/Arachidonate 5-Lipoxygenase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Discontinued drugs in 2006: anti-infectives.
Next Document: Antiangiogenic agents for the treatment of glioblastoma.